

**Errata to the GSK Briefing Document for the Cardiovascular and Renal
Drugs Advisory Committee (CRDAC) Meeting for NDA 216951;
Daprodustat**

CRDAC Meeting Date: October 26, 2022

Page numbers refer to PDF page number in the GSK Briefing Document

I. Noted Errata in the GSK Briefing Document

GSK wishes to note the following errata in the sponsor briefing document (**bold** represents added text, ~~strike through~~ represents deleted text):

- Page 74 of 133
 - ~~Fifty-five~~ **Sixty-three** patients (~~45~~**52**%) had reported a prior history of HF, and ~~80~~ **69** patients (~~66~~ **57**%) reported risk factors for CV diseases.